Accueil>>Lipids>> P450>>Metyrapone

Metyrapone (Synonyms: NSC 25265, SU 4885)

Catalog No.GC17411

La métyrapone (Su-4885) est un inhibiteur de la 11β-hydroxylase puissant et actif par voie orale et un activateur de l'autophagie, inhibe également la production d'aldostérone.

Products are for research use only. Not for human use. We do not sell to patients.

Metyrapone Chemical Structure

Cas No.: 54-36-4

Taille Prix Stock Qté
10mM (in 1mL DMSO)
44,00 $US
En stock
100mg
48,00 $US
En stock
500mg
144,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Metyrapone is a potent oral 11β-hydroxylase inhibitor and autophagy activator that also inhibits aldosterone production. It can be used in the study of depression, atherosclerosis and cancer[1,2].

Metyrapone (100μM; 2h) hyperactivates autophagy in HepG2, and delays the activation of apoptosis at severe endoplasmic reticulum (ER) stress[3]. In H295R cells, treatment with Metyrapone (20μM; 48h) for 48 hours significantly reduced cortisol levels, which were 25.2±4.3μg/L in untreated cells and decreased to 18.9±0.3μg/L after Metyrapone treatment[4].

Neuronal loss in the hippocampal CAl region was significantly reduced in the 4VO model in rats administered Metyrapone (200 mg/kg; sc; 30 min before ischaemia)[5]. There was significant impairment of ovarian and uterine development in the young female Metyrapone-treated (100mg/kg; ip; 30d) mice with the incidence of corpora lutea being reduced 82%. Seminal vesicle and body weights were significantly reduced in juvenile males[6]. Metyrapone (100mg/kg; ip; 4 weeks) treatment reduced the relative mRNA expression levels of phosphoenolpyruvate carboxykinase, a gluconeogenic GR target gene, in the liver and was associated with increased relative mRNA expression levels of the adrenal high-density lipoprotein receptor, SR-BI, and the steroidogenic enzymes, CYP11A1 and CYP11B[7].

References:
[1]. Roozendaall B, Bohus B, McGaugh J L. Dose-dependent suppression of adrenocortical activity with metyrapone: effects on emotion and memory[J]. Psychoneuroendocrinology, 1996, 21(8): 681-693.
[2]. Jahn H, Schick M, Kiefer F, et al. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial[J]. Archives of general psychiatry, 2004, 61(12): 1235-1244.
[3]. Holczer M, Márton M, Kurucz A, et al. A comprehensive systems biological study of autophagy‐apoptosis crosstalk during endoplasmic reticulum stress[J]. BioMed research international, 2015, 2015(1): 319589.
[4]. Germano A, Saba L, De Francia S, et al. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells[J]. PloS one, 2018, 13(5): e0196931.
[5]. Lidhar N K, Darvish-Ghane S, Sivaselvachandran S, et al. Prelimbic cortex glucocorticoid receptors regulate the stress-mediated inhibition of pain contagion in male mice[J]. Neuropsychopharmacology, 2021, 46(6): 1183-1193.
[6]. Pasley J N, McKinney R D, Blue L R. Effects of metyrapone on reproductive organs of house mice[J]. Proceedings of the Society for Experimental Biology and Medicine, 1975, 148(2): 333-336.
[7]. van der Sluis R J, van den Aardweg T, Sijsenaar T J P, et al. Metyrapone Treatment Protects Low-Density Lipoprotein Receptor Knockout Mice against Hypercorticosteronemia Development without Changing Atherosclerosis Susceptibility[J]. Biomolecules, 2023, 13(9): 1287.

Avis

Review for Metyrapone

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Metyrapone

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.